# Young-Onset Dementia

**Chaudhary Muhammad Ahmed**

1st Year MBBS, Islamabad Medical and Dental College, Islamabad, Pakistan

***Key points:***

- Understanding Young-Onset Dementia
- Types and Causes
- Symptoms and Diagnosis
- Management and Treatment
- Recent Advances in Research
- Conclusion

**Understanding Young-Onset Dementia**

Young-Onset Dementia (YOD) refers to dementia diagnosed before the age of 65, making up about 5–10% of all dementia cases[1]. Unlike the more common late-onset dementia that affects older adults, YOD occurs when people are still actively working, raising families, and managing responsibilities. This early onset can lead to significant disruptions in careers, relationships, and financial stability[2].

While Alzheimer's Disease (AD) is the leading cause, YOD can also stem from other conditions like frontotemporal dementia (FTD), vascular dementia, and neurodegenerative diseases such as Huntington's disease[3]. Unfortunately, YOD is often misdiagnosed as depression, anxiety, or stress-related conditions, leading to delays in proper medical care[4].

**Types and Causes of YOD**

YOD can arise from various neurodegenerative and systemic disorders. Here are some of the most common ones:

- Early-Onset Alzheimer's Disease (EOAD)

EOAD accounts for a significant portion of YOD cases and is often linked to genetic mutations in APP, PSEN1, and PSEN2 genes[5]. These mutations interfere with amyloid-beta processing, leading to toxic protein buildup and cognitive decline.

- Frontotemporal Dementia (FTD)

Unlike AD, FTD initially affects personality, behavior, and language rather than memory[6]. It is associated with genetic mutations in C9orf72, MAPT, and GRN, leading to deterioration of the brain's frontal and temporal lobes.

- Vascular Dementia

Caused by reduced blood flow to the brain due to strokes or small vessel disease, vascular dementia primarily affects problem-solving abilities and processing speed.[3]

- Dementia with Lewy Bodies (DLB)

This condition presents with fluctuating cognitive abilities, visual hallucinations, and motor symptoms similar to Parkinson's Disease[6]. It occurs due to the accumulation of abnormal protein deposits in the brain.

- Other Causes
    - Huntington's Disease: A rare genetic disorder causing movement difficulties and cognitive decline.
    - Autoimmune and Metabolic Disorders: Diseases like multiple sclerosis, lupus, and Wilson's disease can sometimes lead to YOD[5].

**Symptoms**

The symptoms of YOD can vary widely and may differ from typical late-onset dementia. In many cases, early signs include behavioral, language, or motor impairments rather than memory loss.

Key Symptoms:
Behavioral and Personality Changes: Common in FTD, leading to social withdrawal, impulsivity, and mood swings.
Language Difficulties: Problems with speech production and understanding, particularly in primary progressive aphasia (PPA).
Cognitive Decline: Memory loss and difficulties with problem- solving, more common in EOAD[5]
Motor Symptoms:
Tremors, rigidity, and coordination issues, often seen in DLB and Huntington's Disease.

**Diagnosis**

To confirm YOD, doctors use a combination of clinical assessments, imaging, and biomarker tests:
Neuroimaging (MRI, CT, PET scans): Helps detect brain atrophy, vascular issues, or Lewy body deposits.
Genetic Testing: Identifies hereditary mutations linked to EOAD and FTD[6].
Neuropsychological Assessments: Evaluates memory, reasoning, and other cognitive functions.

**Management and Treatment of YOD**

Currently, there is no cure for YOD, but treatments focus on improving quality of life and managing symptoms.

**Medications**

- Cholinesterase Inhibitors (Donepezil, Rivastigmine): Help improve cognitive function in EOAD and DLB[7].
- NMDA Receptor Antagonists (Memantine): Regulate glutamate levels to support memory and attention.
- Antidepressants and Antipsychotics: Manage behavioral and mood disturbances, particularly in FTD[5].

**Supportive Therapies**

1. Gene Therapy

CRISPR-based gene-editing techniques are being explored to correct mutations associated with EOAD and FTD[6].

2. Biomarker Development
Advanced testing of blood and cerebrospinal fluid biomarkers (such as tau and amyloid-beta proteins) is improving early detection and accuracy in diagnosing YOD[7].

3. Targeted Drug Therapies
•Anti-Amyloid Drugs (Lecanemab, Aducanumab): Designed to reduce amyloid plaque buildup and slow the progression of EOAD[5].
• Tau Protein Inhibitors: A promising area of study aiming to halt neurodegeneration.

Other:

- Cognitive and Behavioral Therapy: Helps maintain mental function and coping strategies.
- Psychosocial Support: Support groups for patients and caregivers provide emotional and practical assistance.
- Lifestyle Adjustments: Regular exercise, mentally stimulating activities, and a Mediterranean diet may slow disease progression[5].

## Conclusion

Young-Onset Dementia presents unique challenges, as it affects individuals in their prime working and family years. While there is no cure, advances in genetic research, biomarker testing, and new drug treatments provide hope for improved outcomes [1.] Early diagnosis, greater awareness, and specialized care programs are essential for enhancing the lives of those affected by YOD and their families[3,4]

## References


1. Wolff L, Quan Y, Perry G, Forde Thompson W. Music engagement as a source of cognitive reserve. American Journal of Alzheimer's Disease & Other Dementias®. 2023 Nov 4;38:15333175231214833.
2. Ritchie K, Lovestone S. The dementias. The Lancet. 2002 Nov 30; 360(9347):1759-66
3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia. 2011 May; 7(3):263-9
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19; 297(5580):353-6.
5. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical pharmacology. 2014 Apr 15;88(4):640-51
6. Salloway, S., et al. (2021). Aducanumab in early Alzheimer’s disease: A randomized trial. The Lancet, 397(10284), 1937-1945
7. Nan H, Chu M, Jiang D, Liang W, Li Y, Wu Y, Wang Z, Wu L. Identification and characterization of variants in PSEN1, PSEN2, and APP genes in Chinese patients with early-onset Alzheimer's disease. Alzheimer's Research & Therapy. 2025 Dec;17(1):1-8.